News Information
Focusing on cutting-edge technology and conveying industry voices
In protein engineering and antibody–drug conjugate (ADC) research, achieving “precise site-specific modification” of proteins has long been a critical scientific challenge. Traditional protein‑modification strategies typically rely on random reactions with the side chains of natural amino acids, leading to inherent uncertainties in modification sites, modification ratios, and product heterogeneity—factors that significantly impact both functional studies and drug development. In recent years, a biological strategy based on Genetic Code Expansion (GCE) has gained increasing attention. By reprogramming the protein translation machinery, this approach incorporates non‑natural amino acids at predefined codon positions during protein synthesis, enabling precise structural design of proteins at the expression stage. Unlike conventional methods that depend on post‑translational modifications, GCE shifts the control point upstream to the protein biosynthesis process itself, transforming protein modification from a stochastic event into a programmable, translational‑level process. This dramatically enhances the specificity and consistency of site‑directed modifications. This strategy offers a more precise and controllable biological platform for applications such as antibody–drug conjugation, protein labeling, and the design of functional proteins. In this live session, we will explore the principles and applications of site‑specific incorporation of non‑natural amino acids, highlighting their significance in ADC development and protein engineering.
2026/06/10
On the morning of May 20, the technical team of Suzhou Perotin Biotechnology Co., Ltd. paid an invited visit to the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, where they delivered a special report on “Cell-Free Protein Expression Technology and Recent Advances in Its Applications.” Key researchers and graduate student representatives from the institute attended the event, and the ensuing discussions were both substantive and in-depth.
2026/05/29
On June 4–5, the 2026 Pharma Future Summit will grandly open at the Kempinski Hotel Suzhou Jinji Lake. This year’s summit adopts a holistic, full‑industry‑chain perspective, bringing together top decision‑makers to build a closed-loop, collaborative ecosystem. It focuses on breaking through barriers in the industrialization of cutting-edge technologies and on global strategic planning, reshaping the paradigm of pharmaceutical innovation and collaboration. Sub‑Venue 7: AI Session Keynote Topic 1: “The Revolution of AI in Drug Discovery” Cui Jinhui, CEO of Suzhou Perotin Bio: “Generative AI Coupled with Cell-Free Protein Expression: Empowering Innovation at the Source of Drug Development” 📍June 4–5, Kempinski Hotel Suzhou Jinji Lake
2026/05/28
The editor shares with you a groundbreaking achievement published in Nature Communications by the Southwest Hospital of the Third Military Medical University: TRACKer (Target-Responsive non‑preAmplification Cell‑free diagnostic Kit), a low‑cost, scalable solution. Leveraging cell‑free protein synthesis (CFPS) technology, the research team has streamlined the entire assay workflow to just 70 minutes (the CFPS kit was supplied by Suzhou Perotin Biotechnology Co., Ltd.).
2026/05/28
To establish a platform for research collaboration between universities and enterprises, disseminate cutting-edge biotechnological innovations, and support the advancement of research and education in synthetic biology and biopharmaceuticals, on May 25, Perotin Bio, in partnership with the Kasma Platform, visited the Southern University of Science and Technology to jointly foster campus‑based scientific innovation.
2026/05/26
Recently, Dr. Li Xiaobo, Deputy General Manager of Suzhou Perotin Biotechnology Co., Ltd. (hereinafter referred to as “Perotin Bio”), along with his delegation, paid an in-depth visit to Shuimu Future—world’s largest specialized electron microscopy service company, backed by investment from Tsinghua University—and engaged in fruitful technical exchanges.
2026/05/21
In the biomedical field, peptides hold a critical position as therapeutics, playing key roles in disease-related metabolic reprogramming and immune regulation. Thanks to their excellent biocompatibility and high specificity, they have become a highly reliable choice for clinical treatments.
2026/05/21
The official website of Suzhou Perotin Biotechnology Co., Ltd. has been completely revamped and officially launched.
2026/05/21
How many “stumbling blocks” have you encountered on the path of research and development? In the discovery of innovative drug targets and cutting-edge basic research, there are always certain proteins that leave conventional cell expression systems—such as E. coli or mammalian cells—completely stumped: Membrane proteins that precipitate as soon as they’re expressed? Toxic proteins that cause host cells to die upon expression? Or highly unstable proteins with extremely complex structures that degrade easily?…
2026/05/21
Recently, Dr. Li Xiaobo, Chief Marketing Advisor at Perotin Bio, was invited to visit the Institute of Materia Medica, Chinese Academy of Medical Sciences, where he delivered a specialized academic lecture on cell-free protein expression technology. A large number of researchers from the institute attended and participated in the session.
2026/04/27
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
